Posted in | News | Nanomedicine | Nanoanalysis

Agilent Unveils New HPLC-Chip for N-Glycan Analysis

Agilent Technologies Inc. (NYSE:A) today introduced a new HPLC-Chip to address N-glycan analysis in the emerging biopharmaceutical market.

The mAb-Glyco-Chip is designed for the analysis of N-glycans associated with monoclonal antibody molecules.

The mAb-Glyco-Chip is designed for the analysis of N-glycans associated with monoclonal antibody molecules. N-glycans and monoclonal antibody molecules are a critical part of biopharmaceutical research and analysis. A unique product for a specific requirement, the mAb-Glyco-Chip improves the productivity of biopharmaceutical analysis at least 20 times when compared to the current CE-FLD method, and at least five times when compared to the current MALDI-MS method.

“The mAb-Glyco-Chip offers dramatic productivity improvements and addresses a growing need in the biopharmaceutical analysis market,” said Patrick Kaltenbach, general manager for Agilent’s Liquid Phase Separations Business. “Our growing portfolio of HPLC-Chip/MS solutions is an indication of our commitment to advancing microfluidic LC workflows. The launch of this new chip is a wonderful way to celebrate five years of success in the commercial microfluidic LC market.”

Conventional methods of N-glycan analysis, such as LC-FLD or CE-FLD, can take two to three days for completing one single analysis. The new HPLC-Chip/MS workflow significantly reduces the total analysis (including on-chip enzymatic reaction, glycan separation and MS analysis) to tens of minutes. This creates a major productivity enhancement for biopharmaceutical analysis. Coupled with an Agilent Accurate Mass TOF or Q-TOF mass spectrometer, the combined system allows for complete, rapid characterization and quantitative profiling of glycan structures on recombinant antibodies.

The Agilent 1200 Series HPLC-Chip/MS system is a microfluidic chip-based technology for nanospray LC/MS. Agilent pioneered the HPLC-Chip/MS concept in 2005, combining nanoflow HPLC columns, and connecting capillaries and a spray emitter, into a re-useable, credit card-size device. This allowed the advantages of high-sensitivity and low-sample consumption provided by nano LC/MS to be accessible to scientists without the troublesome setup involving microvalve, fittings and capillary tubing of conventional nano LC.

Agilent now offers 13 versions of HPLC-Chips. All Agilent HPLC-Chips are compatible across the entire portfolio of Agilent mass spectrometers for applications that include, but not limited to, peptide quantitation, biomarker discovery, targeted phosphopeptide analysis, glycan and Monoclonal Antibody characterization, and small molecule DMPK studies. In addition, Agilent’s custom chip program delivers customized solutions to individual needs.

Source: http://www.home.agilent.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Agilent Technologies Inc.. (2019, February 13). Agilent Unveils New HPLC-Chip for N-Glycan Analysis. AZoNano. Retrieved on December 03, 2024 from https://www.azonano.com/news.aspx?newsID=17668.

  • MLA

    Agilent Technologies Inc.. "Agilent Unveils New HPLC-Chip for N-Glycan Analysis". AZoNano. 03 December 2024. <https://www.azonano.com/news.aspx?newsID=17668>.

  • Chicago

    Agilent Technologies Inc.. "Agilent Unveils New HPLC-Chip for N-Glycan Analysis". AZoNano. https://www.azonano.com/news.aspx?newsID=17668. (accessed December 03, 2024).

  • Harvard

    Agilent Technologies Inc.. 2019. Agilent Unveils New HPLC-Chip for N-Glycan Analysis. AZoNano, viewed 03 December 2024, https://www.azonano.com/news.aspx?newsID=17668.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.